AEE788 是一种有效的EGFR和HER2/ErbB2抑制剂，IC50分别为2 nM和6 nM，对VEGFR2/KDR， c-Abl， c-Src，和Flt-1作用效果稍弱，对Ins-R， IGF-1R， PKCα和CDK1没有抑制作用。AEE788也抑制KDR, c-Abl, c-Src,和Flt-1，IC50为50-80 nM。AEE788对ErbB-4, PDGFR-β, Flt-3, Flt-4, RET,和c-Kit没有作用效果，也不抑制Ins-R, IGF-1R, PKC-α,和PKA。AEE788作用于A431细胞，有效抑制EGFR磷酸化，IC50为11 nM。

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

NVP-AEE 788

DMSO ：82 mg/mL (186.1 mM)

EGFR ,HER2/ErbB2 ,c-Abl ,FLT1 ,c-Fms

AEE788 also inhibits KDR, c-abl, c-Src, and Flt-1 with IC50 of 50-80 nM. AEE788 is not sensitive to ErbB-4, PDGFR-β, Flt-3, Flt-4, RET, and c-Kit and has no inhibitory to Ins-R, IGF-1R, PKC-α, and PKA. AEE788 potently inhibits EGFR phosphorylation in A431 cells with IC50 of 11 nM. AEE788 also inhibits the phosphorylation of KDR in CHO cells and erbB2 in BT-474 cells, without any effects on PDGF-induced phosphorylation in A31 cells. AEE788 inhibits the proliferation of NCI-H596, MK, BT-474 and SK-BR-3 cells with IC50 of 78, 56, 49 and 381 nM, respectively. Otherwise, AEE788 has the additional property of inhibiting cellular proliferation driven by EGFR mutant including 32D/EGFR and 32D/EGFRvIII. AEE788 furtheralso inhibits both EGF- and VEGF-driven HUVEC proliferation with IC50 of 43 and 155 nM, respectively. AEE788 inhibits the phosphorylation of EGFR, VEGFR2, Akt, and MAPK in human cutaneous SCC cell lines (Colo16, HaCaT, SRB1, and SRB12 cells), which leads to growth inhibition and induction of apoptosis. AEE788 inhibits the phosphorylation of EGFR and Akt in HT29 cells at 0.2 to 1.0 μM. AEE788 inhibits cell proliferation and prevents EGF- and neuregulin-induced HER1, HER2, and HER3 activation in medulloblastoma cell lines. AEE788 shows growth-suppressive activities in chemosensitive and chemoresistant medulloblastoma cells.

AEE788 produces a dose-dependent inhibition of tumor growth in NCI-H596 or DU145 xenograft models, with only minor body weight changes. AEE788 induces tumor regression by 57% at 50 mg/kg in the NeuT/erbB2 GeMag model. AEE788 potently inhibits EGF-induced EGFR phosphorylation in A431 tumors and erbB2 phosphorylation in GeMag tumors. AEE788 dose-dependently inhibited angiogenesis induced by VEGF and does not inhibit bFGF-induced angiogenesis. AEE788 suppresses the growth of tumor volume by 54% in Colo16 xenografts at 50 mg/kg, which dues to the inhibition of phosphorylation of EGFR, VEGFR, Akt, and MAPK. AEE788 (50 mg/kg) also inhibits growth of tumors in the cecum and peritoneum (>50%) and reduces the incidence of lymph node metastasis to 70% in HT29 cells implanted in the cecum of nude mice, without loss of body weight and gross evidence of neovascularization. AEE788 significantly lowers the expression levels of pEGFR and pVEGFR in HT29 cecal tumors and does not alter those of EGF, VEGF, EGFR, or VEGFR. Combined with CPT-11, AEE788 has significantly smaller tumors and complete inhibition of lymph node metastasis. AEE788 inhibits the growth of Daoy, DaoyPt, and DaoyHER2 xenografts by 51%, 45%, and 72%, respectively. AEE788 could promote LBH589-mediated generation of reactive oxygen species in K562 tumor cells, which in turn increase apoptosis.

AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
Venkatesanet al. Life Sci. 2012 Aug 23. PMID: 22922496.
䔸Żᩄ族痛셌Ų族痛셌ŲItem褐Count๏
﯈趌๐侮᠜׶靴๟
ᠠ׶iS￿￿ññ眘⮦眀⮦敲痛๏
ࠃ馸๟鳘๟௼଩祖ItemDzǷ„Count洣盜᬴叫㺍痭ᠠ׶靴๟i縉靴๟蘿敌ଧ靴๟ᠠ׶i᭰叫㺍痭ᡸ׶顴๟਋먲ନ魈๟鸤๟�ଭ鶔๟׶懲랖ନ࢒煮ﭬz�ଭ鶔๟삲W鸤๟ᨼĊ煮섈W豈勤섫W豈཰́煮ﭬz
섪W섲W཰́褐ﭔzᇈMoveEof„DzǷꯍ�혐珂„劬盜蠊똉Ⴚ啑盜ᦤ叫㺍痭ᠠ׶靴๟i侮﯈褐靴๟婢敌ଧ靴๟ᠠ׶i靴๟䢸Ş䢸Ş⌅痜Ѐ￾￿￾￿ꁠ๒⌅痜
Ѐ䢸Ş￾￿쿹࡜痮Љ
䕄Ż顴๟蘿ॡ痮 ᤀ
ꋔŻ
蘿ᩄᡴ׶冨๘瑉浥ᛨ׶擄୔ᡴ׶冨๘潃湵tw௪讻Q௪④Q„௪劬盜躂똉Ⴚ啑盜勐盜�✰혐珂Ⴚ뼠Ǖ
Ȁ Àז梕盜
DzǷ„ 曀盞$䢸Ş戀䢸Ş輦⌅痜⌅痜穀Ѐ￾￿￾￿ꁠ๒
䢸Ş䢸Şݗ痮캙ݗ痮裂࡜痮Љ
䲈Ż穀滛ॡ痮縉S穀S뵔Ż
滛ↈ᠜׶吀๘潅f楜Q௪DzǷ„„௪„爃G㵈̈́爋G㵀̈́௪麘̀揋Q揢Q„컜瞲„ສŘ௪

ࠀຑ
䞫盞
ࠀȎ

ࠀȂมȂȎȎȎ߄睠얠Š￿￿￿￿ȂȂȎ瀐ͤ